triamcinolone acetonide


Siu Guan


Averroes Pharma
Concise Prescribing Info
Triamcinolone acetonide
Nonsuppurative thyroiditis; adjunctive therapy for short-term administration in post-traumatic OA, synovitis of OA, RA, acute & subacute bursitis, epicondylitis, acute non-specific tenosynovitis, acute gouty arthritis, psoriatic arthritis, ankylosing spondylitis; juvenile RA. Acute rheumatic carditis. Pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), seborrheic dermatitis & psoriasis, exfoliative dermatitis, bullous dermatitis herpetiformis. Severe allergic, ophth, GI, resp, hematologic & neoplastic diseases. Edema.
Dosage/Direction for Use
IM Adult & childn >12 yr Initially 60 mg, adjusted to 40-80 mg. Childn 6-12 yr 40 mg. IA/IB inj into tendon sheaths Small joints: Initially 2.5-5 mg. Max: 10 mg. Larger joints: Initially 5-15 mg. Max: 40 mg.
Hypersensitivity. Systemic infections unless specific anti-infective therapy is employed. Not for IV, intrathecal or intraocular inj. Childn up to 3 yr, newborn, premature infants.
Special Precautions
Anaphylactoid reactions. Recent intestinal anastomoses, diverticulitis, thrombophlebitis, existing or previous history of severe affective disorders (especially previous steroid psychosis), exanthematous disease, metastatic carcinoma, osteoporosis (post-menopausal females are particularly at risk); active or history of peptic ulcer. Myasthenia gravis. Latent or healed TB; presence of local or systemic viral infection, systemic fungal infections or active infections not controlled by antibiotics. Acute psychoses & glomerulonephritis. HTN; CHF; glaucoma or family history of glaucoma; previous steroid myopathy or epilepsy. Hypo- & hyperthyroidism, cirrhosis. DM. Menstrual irregularities. Prolonged therapy. Avoid live vaccines & exposure to measles. Chronic nephritis or renal insufficiency. Hepatic failure. Pregnancy & lactation. Childn <6 yr. Elderly.
Adverse Reactions
Anti-inflammatory & immunosuppressive effects; fluid & electrolyte disturbances; musculoskeletal, dermatological, GI, neurological, endocrine & ophth disturbances, hypersensitivity reactions, necrotising angiitis, thrombophlebitis, thromboembolism, leucocytosis, insomnia & syncopal episodes, administration site reactions; w/drawal symptoms.
Drug Interactions
Antagonised anticholinesterase, antihypertensives, diuretic effects. Potentiated or decreased anticoagulants. Increased blood glucose. Enhanced hypokalemic effect, possibility of digitalis toxicity. Decreased serum conc of INH; clearance by estrogens, OC, ketoconazole, thyroid drugs. Increased toxicity of cyclosporin. Increased metabolic clearance by barbiturates, phenytoin, carbamazepine, rifampicin, primidone, aminoglutethimide. Inhibited growth promoting effect of human growth hormone. Increased GI bleeding & ulceration incidence &/or severity w/ NSAIDs.
MIMS Class
Corticosteroid Hormones
ATC Classification
H02AB08 - triamcinolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
Sivkort susp for inj (amp) 40 mg/mL
10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in